News
We send the latest information from SMC Laboratories.
【Case Study】Why do disease model mice change the outcomes?
If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of …
Introduction of [Pathway MAP of MASH compounds] to accelerate your research
When conducting non-clinical research, it is important to choose an appropriate mouse model that reproduces hu…
Preclinical COPD study with positive controls, Roflumilast
Today, we share an update regarding new preclinical service. It is now possible to use a positive control (Rof…
Introduction of Chronic Kidney Disease Mice Models
I am writing you today to share some information on our chronic kidney disease (CKD) models. CKD is a c…
Cholangiocarcinoma and Primary sclerosing cholangitis
On February 15, World Cholangiocarcinoma Day! Today we would like to introduce cholangiocarcinoma (CCA,…
Press Release Regarding STAM-HCC/IO+ Mice has been distributed.
We are pleased to announce that our STAM(TM)-HCC/IO+ mouse was introduced in PR Newswire (Kyodo News JBN). For…
Study published in Sci Transl Med. on the effects of A monoclonal antibody targeting nonjunctional claudin-1 in CKD of UUO model.
We introduce a case study of drug efficacy evaluation of anti-claudin-1 antibody using our chronic kidney dise…
Announcement of webinar 【MASH-Liver cancer model mouse_Pharmacology study for MASH/fibrosis targeting GLP-1】
Today, we are excited to invite you to join our Webinar that will be taking place on January 25th from 9:30 AM…
MOA demonstration #1 【microbiota】| MASH treatment and fibrosis prevention study targeting gut microbiota in STAM mice
Today, we would like to introduce a demonstration example of a drug efficacy evaluation test of a bacterial co…
Fibrosis is involved in many diseases and disease-related deaths
Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments tha…